Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 341-355 , April 2008

Mechanisms of bone metastasis in prostate cancer: clinical implications

References 

  1. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Research. 1993;13:443–449
  2. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Critical Reviews in Oncology/Hematology. 1995;18:51–64
  3. Koutsilieris M, Sourla A, Pelletier G, et al. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. Journal of Bone and Mineral Research. 1994;9:1823–1832
  4. Sourla A, Doillon C, Koutsilieris M. Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Research. 1996;16:2773–2780
  5. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology. 2000;31:578–583
  6. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Pathology. 2003;34:646–653
  7. Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. The Prostate. 1983;4:569–577
  8. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. The Journal of the American Medical Association. 1999;281:1591–1597
  9. Tolis G, Faure N, Koutsilieris M, et al. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration. Journal of Steroid Biochemistry. 1983;19:995–998
  10. Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. The Journal of Urology. 1993;150:908–913
  11. Koutsilieris M, Laroche B, Thabet M, et al. The assessment of disease aggressivity in stage D2 prostate cancer patients. [review] Anticancer Research. 1990;10:333–336
  12. Reyes-Moreno C, Sourla A, Choki I, et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology. 1998;52:341–347
  13. Charlesworth PJ, Harris AL. Mechanisms of disease: angiogenesis in urologic malignancies. Nature Clinical Practice. 2006;3:157–169
  14. Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis?. Anticancer Research. 1997;17:1541–1549
  15. Dimitriadou V, Mecheri S, Koutsilieris M, et al. Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. Journal of Leukocyte Biology. 1998;64:791–799
  16. Janvier R, Sourla A, Koutsilieris M, et al. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Research. 1997;17:1551–1557
  17. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Research. 2005;65:11230–11235
  18. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, et al. Animal models of bone metastasis. Cancer. 2003;97:748–757
  19. Chay CH, Cooper CR, Gendernalik JD, et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology. 2002;60:760–765
  20. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion & Metastasis. 1994;14:303–308
  21. Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. The Journal of Clinical Investigation. 2004;114:560–568
  22. Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46:681–686[discussion: 6–7]
  23. Batson OV. The vertebral system of veins as a means for cancer dissemination. Progress in Clinical Cancer. 1967;3:1–18
  24. Ghossein RA, Scher HI, Gerald WL, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. Journal of Clinical Oncology. 1995;13:1195–1200
  25. Karamanolakis D, Bogdanos J, Sourla A, et al. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Molecular Medicine (Cambridge, Mass.). 2002;8:667–675
  26. Koutsilieris M, Lembessis P, Luu-The V, et al. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clinical & Experimental Metastasis. 1999;17:823–830
  27. Mitsiades CS, Lembessis P, Sourla A, et al. Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clinical & Experimental Metastasis. 2004;21:495–505
  28. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews. 1989;8:98–101
  29. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. Journal of the National Cancer Institute. 1998;90:118–123
  30. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Reviews. 1992;11:353–375
  31. Bogdanos J, Karamanolakis D, Tenta R, et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocrine-Related Cancer. 2003;10:279–289
  32. Koutsilieris M, Bogdanos J, Milathianakis C, et al. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opinion on Investigational Drugs. 2006;15:795–804
  33. Koutsilieris M, Mitsiades C, Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Molecular Medicine (Cambridge, Mass.). 2000;6:251–267
  34. Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. The Prostate. 1999;38:313–316
  35. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:3540–3545
  36. Holen I, Croucher PI, Hamdy FC, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research. 2002;62:1619–1623
  37. Mori K, Le Goff B, Charrier C, et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone. 2007;40:981–990
  38. Fizazi K, Yang J, Peleg S, et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clinical Cancer Research. 2003;9:2587–2597
  39. Koutsilieris M, Frenette G, Lazure C, et al. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Research. 1993;13:481–486
  40. Koutsilieris M, Rabbani SA, Bennett HP, et al. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. The Journal of Clinical Investigation. 1987;80:941–946
  41. Polychronakos C, Janthly U, Lehoux JG, et al. Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. The Prostate. 1991;19:313–321
  42. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. The Journal of Clinical Investigation. 2001;107:1235–1244
  43. Koutsilieris M, Rabbani SA, Goltzman D. Selective osteoblast mitogens can be extracted from prostatic tissue. The Prostate. 1986;9:109–115
  44. Koutsilieris M, Rabbani SA, Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. The Journal of Endocrinology. 1987;115:447–454
  45. Mitsiades C, Bogdanos J, Karamanolakis D, et al. Bone microenvironment participation in the development of androgen ablation in prostate cancer patients with bone metastases: clinical application of an anti-survival factor therapy. In:  Labrie F,  Koutsilieris M editor. Prostate cancer: understanding the pathophysiology and re-designing a therapeutic approach. Athens: Paschalidis Medical Publications; 2004;p. 109–134
  46. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine. 1995;1:944–949
  47. Koutsilieris M, Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Research. 1992;12:905–910
  48. Edlund M, Sung SY, Chung LW. Modulation of prostate cancer growth in bone microenvironments. Journal of Cellular Biochemistry. 2004;91:686–705
  49. Tenta R, Sourla A, Lembessis P, et al. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et métabolisme. 2005;37:593–601
  50. Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opinion on Investigational Drugs. 2001;10:1099–1115
  51. Reyes-Moreno C, Frenette G, Boulanger J, et al. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. The Prostate. 1995;26:260–269
  52. Labrie F, Dupont A, Cusan L, et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine. 1993;16:499–509
  53. Labrie F, Dupont A, Suburu R, et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clinical and Investigative Medicine. 1993;16:425–439
  54. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. The Journal of Urology. 2001;165:119–125
  55. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. The Journal of the American Medical Association. 1999;281:1598–1604
  56. Koutsilieris M, Faure N, Tolis G, et al. Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology. 1986;27:221–228
  57. Koutsilieris M, Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. The Prostate. 1985;7:31–39
  58. Koutsilieris M, Tenta R, Tiblalexi D, et al. Bone metastasis microenvironment participates in the development of androgen ablation refractoriness and chemotherapy resistance of prostate cancer cells residing in the skeleton: clinical implications. In:  Meadows G editors. Integration/interaction of oncologic growth. Springer; 2005;p. 335–344
  59. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. Journal of the National Cancer Institute. 1999;91:1113–1124
  60. Athanassiadou P, Grapsa D. Recent advances in the detection of bone marrow micrometastases: A promising area for research or just another false hope? A review of the literature. Cancer Metastasis Reviews. 2006;25:507–519
  61. Sourla A, Lembessis P, Mitsiades C, et al. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Research. 2001;21:3565–3570
  62. Lembessis P, Msaouel P, Halapas A. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clinical Chemistry and Laboratory Medicine. 2007;45:1488–1494
  63. Lembessis P, Sourla A, Mitsiades C, et al. Molecular staging in clinically localized and advanced prostate cancer. In:  Labrie F,  Koutsilieris M editor. Prostate cancer: understanding the pathophysiology and re-designing a therapeutic approach. Athens: Paschalidis Medical Publications; 2004;p. 97–107
  64. Mitropapas G, Nezos A, Halapas A, et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clinical Chemistry and Laboratory Medicine. 2006;44:1403–1409
  65. de Cremoux P, Ravery V, Podgorniak MP, et al. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. European Urology. 1997;32:69–74
  66. Lintula S, Stenman UH. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. The Journal of Urology. 1997;157:1969–1972
  67. Loric S, Dumas F, Eschwege P, et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clinical Chemistry. 1995;41:1698–1704
  68. Koutsilieris M, Reyes-Moreno C, Sourla A, et al. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Research. 1997;17:1461–1465
  69. Kruit A, Reyes-Moreno C, Newling DW, et al. Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin. Anticancer Research. 1999;19:3153–3156
  70. Reyes-Moreno C, Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clinical & Experimental Metastasis. 1997;15:205–217
  71. Koutsilieris M, Dimopoulos T, Milathianakis C, et al. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU International. 2007;100(Suppl. 2):60–62
  72. Msaouel P, Diamanti E, Tzanela M, et al. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opinion on Emerging Drugs. 2007;12:285–299
  73. Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clinical Endocrinology. 1998;48:311–316
  74. Dimopoulos MA, Kiamouris C, Gika D, et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology. 2004;63:120–125
  75. Koutsilieris M, Mitsiades C, Dimopoulos T, et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. The Journal of Clinical Endocrinology and Metabolism. 2001;86:5729–5736
  76. Mitsiades CS, Bogdanos J, Karamanolakis D, et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Research. 2006;26:3693–3700

PII: S1521-690X(08)00012-2

doi: 10.1016/j.beem.2008.01.011

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 341-355 , April 2008

Article Tools

* Image Usage & Resolution